PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds, announced today that the company’s research and development team has completed work on the development of a Microcyn hydrogel formulation. Microcyn-Gel has been specifically designed to address a broad spectrum of applications including potential treatment of various skin disorders (acne, psoriasis, and dermatitis), as well as for use in wound care, cosmeceuticals, animal health care, treatment of burns and as an anti-fungal in foot care.
